D. Clayton

发表

Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis

I. Vavasour, A. Traboulsee, Alexander Rauscher, 2019, Human brain mapping.

Deformation-based morphometry identifies deep brain structures protected by ocrelizumab

N. Tustison, R. Carano, T. Bengtsson, 2022, NeuroImage: Clinical.

PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers

P. Tariot, Yi Su, E. Reiman, 2020, NeuroImage: Clinical.

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Sandra M. Sanabria-Bohórquez, K. Sink, D. Selkoe, 2022, JAMA neurology.

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a

C. Laule, I. Vavasour, A. Traboulsee, 2022, NeuroImage: Clinical.

Evidence that allelic variants of the spinocerebellar ataxia type 2 gene influence susceptibility to multiple sclerosis

P. Goodfellow, S. Sawcer, A. Compston, 1999, Neurogenetics.

A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22

P. Goodfellow, S. Sawcer, A. Compston, 1996, Nature Genetics.

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

J. Cummings, L. Honigberg, D. Clayton, 2014, Alzheimer's & Dementia.

Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer's disease carriers and non‐carriers: Baseline findings from the API ADAD Colombia Trial

P. Tariot, K. Sink, E. Reiman, 2022, Alzheimer's & Dementia.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

S. Salloway, E. Reiman, L. Honigberg, 2018, Alzheimer's Research & Therapy.

ABBY

J. Cummings, L. Honigberg, C. V. van Dyck, 2018, Neurology.

Multiple sclerosis in sibling pairs: an analysis of 250 families

D. Clayton, S. Sawcer, A. Compston, 2001, Journal of neurology, neurosurgery, and psychiatry.

A genome screen for multiple sclerosis in Italian families

D. Clayton, S. Sawcer, A. Compston, 2001, Genes and Immunity.

HLA typing in the United Kingdom multiple sclerosis genome screen

P. Goodfellow, S. Sawcer, A. Compston, 1998, Neurogenetics.

The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen.

P. Goodfellow, D. Clayton, S. Sawcer, 1998, Brain : a journal of neurology.

Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis

D. Miller, D. Kingsley, J. Chataway, 1997, The Lancet.

No linkage between multiple sclerosis and the T cell receptor α chain locus

P. Holmans, N. Wood, M. Eoli, 1994, Journal of the Neurological Sciences.

A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility.

P. Goodfellow, S. Sawcer, A. Compston, 2002, Brain : a journal of neurology.

A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis

P. Goodfellow, S. Sawcer, A. Compston, 1999, Journal of Neuroimmunology.

No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

S. Sawcer, S. Broadley, R. Roxburgh, 2001, Journal of neurology, neurosurgery, and psychiatry.

Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis

S. Sawcer, A. Compston, S. Broadley, 2000, Journal of Neuroimmunology.

CAMPATH-1H in multiple sclerosis

A. Compston, A. Coles, G. Hale, 1996, Multiple sclerosis.

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

A. Compston, A. Compston, G. Hale, 1994, The Lancet.

ABBY

J. Cummings, L. Honigberg, C. V. van Dyck, 2018, Neurology.

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier coh

L. Schneider, P. Tariot, Ronald G. Thomas, 2018, Alzheimer's & dementia.

Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease

A. D. de Crespigny, L. Honigberg, T. Bengtsson, 2021, Neuroimage: Reports.

No evidence for association of multiple sclerosis with the complement factors C6 and C7

P. Goodfellow, S. Sawcer, A. Compston, 1999, Journal of Neuroimmunology.

Parkinson's disease is not associated with the combined α‐synuclein/apolipoprotein E susceptibility genotype

C. Morris, N. Quinn, R. de Silva, 2001, Annals of neurology.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

K. Sink, L. Honig, K. Blondeau, 2020, Journal of Alzheimer's disease : JAD.

P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results

D. Selkoe, L. Honigberg, U. Eichenlaub, 2020, Clinical Neurophysiology.

Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?

Roger Tam, Anthony L Traboulsee, Irene M Vavasour, 2019, Multiple sclerosis journal - experimental, translational and clinical.

Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.

A. D. de Crespigny, R. Carano, T. Bengtsson, 2021, Radiology.

Multi-arm U-Net with dense input and skip connectivity for T2 lesion segmentation in clinical trials of multiple sclerosis

A. D. de Crespigny, R. Carano, Zhuang Song, 2023, Scientific Reports.

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a

A. Traboulsee, Alexander Rauscher, S. Kolind, 2019, Multiple sclerosis journal - experimental, translational and clinical.

Clinical concordance in sibling pairs with multiple sclerosis

D. Clayton, N. Robertson, D. Clayton, 1996, Neurology.

Questionable role of adult‐onset focal dystonia among sporadic dystonia patients

P. Goodfellow, S. Sawcer, A. Compston, 1998, Annals of neurology.

No evidence for the involvement of interleukin 2 or the immunoglobulin heavy chain gene cluster in determining genetic susceptibility to multiple sclerosis

S. Sawcer, S. Broadley, J. Chataway, 2000, Journal of neurology, neurosurgery, and psychiatry.